A share price of Dyne Therapeutics Inc [DYN] is currently trading at $43.60, up 1.23%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DYN shares have gain 6.78% over the last week, with a monthly amount glided 3.91%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on May 21, 2024, when Chardan Capital Markets reiterated its Buy rating and also boosted its price target to $42 from $31. Previously, Morgan Stanley started tracking the stock with Overweight rating on April 30, 2024, and set its price target to $40. On February 20, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $36 on the stock. Raymond James upgraded its rating to a Strong Buy and increased its price target to $27 on February 27, 2023. Oppenheimer initiated its recommendation with a Outperform and recommended $34 as its price target on February 15, 2023. Guggenheim started tracking with a Buy rating for this stock on January 26, 2023, and assigned it a price target of $33. In a note dated July 20, 2022, Chardan Capital Markets initiated an Buy rating and provided a target price of $17 on this stock.
Dyne Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $6.40 and $45.46. Currently, Wall Street analysts expect the stock to reach $38.63 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $43.60 at the most recent close of the market. An investor can expect a potential drop of -11.4% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -70.18%, Pretax Profit Margin comes in at -67.95%, and Net Profit Margin reading is -67.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.11 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.24 points at the first support level, and at 40.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.59, and for the 2nd resistance point, it is at 45.58.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Dyne Therapeutics Inc [NASDAQ:DYN] is 21.83. Further, the Quick Ratio stands at 21.83, while the Cash Ratio is 12.16.
Transactions by insiders
Recent insider trading involved Forbion Capital Fund IV Cooper, Affiliate, that happened on Aug 08 ’24 when 1.02 million shares were purchased. Chief Operating Officer, HIGH SUSANNA GATTI completed a deal on Jun 24 ’24 to sell 10163.0 shares. Meanwhile, Chief Operating Officer HIGH SUSANNA GATTI sold 29787.0 shares on Jun 21 ’24.
